Hyperparathyroidism is an endocrine disorder characterized by excessive parathyroid hormone production, leading to elevated calcium levels and related health complications. According to Durairaj Arjunan et al., 2025, primary hyperparathyroidism is most caused by parathyroid adenoma, accounting for 80–85% of cases, highlighting its clinical significance and rising detection. Current therapies focus on parathyroidectomy and calcimimetics, while the pipeline emphasizes more targeted drug approaches. According to the hyperparathyroidism pipeline analysis by Expert Market Research, increasing research efforts and the growing focus on advanced medical therapies are expected to support strong market growth in the coming years.
Major companies involved in the hyperparathyroidism pipeline analysis include Shanghai Hengrui Pharmaceutical Co., Ltd., Shaanxi Micot Pharmaceutical Technology Co., Ltd., and others.
Leading drugs currently in the pipeline include SHR6508, MT1013, and others.
The growthin the pipeline is supported by rising prevalence of parathyroid disorders, expanded clinical evaluations of calcimimetic therapies, and increased investment in biologics targeting hormone regulation and calcium imbalance.
The Hyperparathyroidism Pipeline Analysis Report by Expert Market Research gives comprehensive insights into hyperparathyroidism therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hyperparathyroidism. The hyperparathyroidism report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hyperparathyroidism pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hyperparathyroidism treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hyperparathyroidism.
Read more about this report - Request a Free Sample
Hyperparathyroidism is a disorder in which the parathyroid glands produce excessive parathyroid hormone, leading to elevated calcium levels in the blood. It often occurs due to gland enlargement, benign tumors, or chronic kidney disease, causing bone loss and kidney complications.
Hyperparathyroidism treatment includes surgery, medications, and calcium management strategies to control hormone levels and prevent complications, improving patient outcomes and quality of life. In August 2024, the hyperparathyroidism market pipeline gained attention as the FDA approved YORVIPATH® (palopegteriparatide), offering a targeted hormone replacement approach that addresses underlying hormonal imbalance and supports long-term disease management.
According to recent studies, the hyperparathyroidism drug pipeline is expanding to address the growing patient population. As per Durairaj Arjunan et al., 2025, primary hyperparathyroidism predominantly affects post-menopausal women, with parathyroid adenoma causing 80–85% of cases, parathyroid hyperplasia 10–15%, and rare parathyroid carcinoma 1–4%. According to Rebecca S. Gates et al., it is the third most-common endocrine disorder after diabetes and thyroid disease, with prevalence in the United States estimated at 233 per 100,000 women and 85 per 100,000 men. These developments highlight a promising focus on targeted therapies and improved disease management.
This section of the report covers the analysis of hyperparathyroidism drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The hyperparathyroidism pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II with 39% covers a major share of the total hyperparathyroidism clinical trials. It is followed by phase III and phase IV, each contributing 28%. This robust distribution across advanced phases indicates strong development momentum, suggesting significant potential to enhance treatment options and drive growth in the hyperparathyroidism market.
The drug molecule categories covered under the hyperparathyroidism pipeline analysis include small molecules, monoclonal antibodies, and peptides. The hyperparathyroidism report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hyperparathyroidism. Parathyroid hormone (PTH)-based therapies are emerging as key treatment options in the hypoparathyroidism pipeline. For instance, Yorvipath (PTH1-34) is under evaluation for chronic hypoparathyroidism in adults and has received MHRA approval in the UK. Additionally, eneboparatide is being investigated in the CALYPSO trial to assess its safety and efficacy in patients with low or absent PTH levels, aiming to improve calcium regulation and reduce disease complications.
The EMR report for the hyperparathyroidism pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hyperparathyroidism therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hyperparathyroidism clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hyperparathyroidism. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hyperparathyroidism drug candidates.
SHR6508 is a novel intravenous allosteric modulator of the calcium-sensing receptor being sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. The Phase 3 trial is actively evaluating its efficacy and safety in Chinese patients with secondary hyperparathyroidism undergoing maintenance hemodialysis. The study is examining how SHR6508 is reducing parathyroid hormone secretion by enhancing receptor sensitivity to calcium ions, potentially improving calcium balance. The objective is to confirm its therapeutic benefits while minimizing gastrointestinal adverse events and improving patient compliance compared to existing treatments such as cinacalcet. Enrollment includes 498 participants across multiple centers.
MT1013 is a first-in-class dual-targeting receptor agonist polypeptide that is simultaneously activating the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, offering rapid and sustained reduction of intact parathyroid hormone levels. The drug is being sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd. in an ongoing Phase IIb clinical study. The study is examining its long-term safety and efficacy in secondary hyperparathyroidism patients with chronic kidney disease undergoing maintenance dialysis. This phase is aiming to evaluate comprehensive control of iPTH, calcium, and phosphorus levels while assessing cardiovascular and bone health benefits.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Hyperparathyroidism Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for hyperparathyroidism. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hyperparathyroidism collaborations, regulatory environments, and potential growth opportunities.
Upto 25% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share